T he European Vaccine Initiative (EVI) proudly participated in the Product Development Partnerships (PDP) IV Annual Meeting on November...

AMR is growing on a global scale and has become a top 10 health threat that affects the effectiveness of antimicrobial medicines.

Two PhD students, Dr. Elizabeth Kibwana and Dr. Caroline Bundi, have successfully defended their dissertations under the Multi-Stage...

The phase Ia/b trial for the InvaplexAR-Detox/dmLT vaccine started at LUMC, in Netherlands.

European Vaccine Initiative (EVI) and the Tuberculosis Vaccine Initiative (TBVI) are proud to announce a new partnership with VAC4EU.

Collaboration will support Controlled Human Infection Model studies to accelerate development of effective and affordable RSV vaccines.

AMR Accelerator asks for long-term investments, emphasising the need to preserve the European capacity to combat drug-resistant infections.

EVI is thrilled to announce the launch of TRANSVAC Academy, a programme providing advanced expert-led training in vaccinology.

The European Pharmacopoeia has announced the end of the rabbit pyrogen testing.

Ethnographic study aiming at understanding local perceptions of pregnancy and vaccinations.

EVI supports and coordinates various clinical trials that contributes to the fight against global health diseases.

The NOSEVAC project, co-funded by the European Commission and coordinated by European Vaccine Initiative (EVI), held its first annual...

Malaria poses a significant threat to public health, disproportionately affecting the most vulnerable populations. EVI strengthens the fight

World Tuberculosis Day serves as a poignant reminder to raise awareness about tuberculosis (TB). Despite the efforts and promising...

The TBVI Governance Board is pleased to announce the appointment of Dr. Ole F. Olesen as their new Executive Director.

The blood-stage malaria vaccine BK-SE36/CpG was found to be safe and induced anti-SE36 antibodies in all cohorts.

Across the globe, women and girls are making remarkable contributions to scientific research, innovation, and discovery.

Untreated NTDs presently affect 1.7 billion individuals globally. The most severely impacted are the impoverished segments of society.

Passionate about making a significant impact in the fields of infectious diseases and AMR? Join DRAIGON.

The ambitious project mission is to develop a novel diagnostic tool to tackle antimicrobial resistance (AMR) through the integration of...

In a significant development, Professor Sam McConkey, the Head of the Department of International Health and Tropical Medicine at RCSI...

AMR poses a significant global threat, with nearly 5 million deaths associated with bacterial AMR in 2019. EVI contributes to the fight.

EVI actively participates in various EDCTP projects such as ShigaPlexIM, PREV_PKDL, MMVC, MIMVaC-Africa, and MVPE-CC, fellowships & more.

In the heart of Wuxi, China, the forum explored the forefront of vaccine R&D with discussions on revolutionary mRNA-based vaccines and more.